HIV-1 neutralizing antibodies: How full is the bottle?

Nature Medicine

Volumn 5, Issue 2, 1999, Pages 142-144

  Moore, John P ^a   Burton, Dennis R ^b  

^a AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANIMALS; CHIMERA; HIV ANTIBODIES; HIV-1; NEUTRALIZATION TESTS; PAN TROGLODYTES; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0032960601     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/5502     Document Type: Short Survey

References (17)

1. Emini, E.A. et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355, 728-730 (1992).
2. Burton, D.R. & Moore, J.P. Why do we not have an HIV vaccine and how can we make one? Nature Med. 4, 495-498 (1998).
3. Letvin, N.L. Progress in the development of an HIV-1 vaccine. Science 280, 1875-1880 (1998).
4. Igarashi, T. et al. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nature Med. 5, 211-216 (1999).
5. Shibata, R. et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature Med. 5, 204-210 (1999).
6. Shibata, R. et al. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1. J. Virol. 70, 4361-4369 (1996).
7. Montefiori, D.C. et al. Neutralizing and infection enhancing antibody responses to human immunodeficiency virus type 1 in long-term non-progressors. J. Infect. Dis. 173, 60-67 (1996).
8. Montefiori, D.C. et al. Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1. J. Virol. 72, 3427-3431 (1998).
9. Zhang, L. et al. Rapid clearance of simian immunodeficiency virus particles from plasma of Rhesus macaques. J. Virol. 73, 855-860 (1999).
10. Sattentau, Q.J. & Moore, J.P. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the glycoprotein gp120 oligomer. J. Exp. Med. 182, 185-196 (1995).
11. Zolla-Pazner, S. et al. Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines. J. Infect. Dis. 178, 1502-1506 (1998).
12. Gauduin, M.-C. et al. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nature Med. 3, 1389-1393 (1997).
13. Zhou, J.Y. & Montefiori, D.C. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells. J. Virol. 71, 2512-2517 (1997).
14. Trkola, A. et al. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J. Virol. 72, 1876-1885 (1998).
15. Belshe, R.B. et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 12, 2407-2415 (1998).
16. Connor, R.I. et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72, 1552-1576 (1998)
17. mne gp160 vaccines in a combination immunization regimen. J. Virol. 73, 618-630 (1999).